Skip to menu Skip to content Skip to footer

2009

Journal Article

Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation

Hall, S. L., Tate, J., Gill, D. and Mollee, P. (2009). Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation. Clinical Biochemist Reviews, 30 (3), 113-118.

Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation

2009

Conference Publication

Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study

Mollee, Peter, Jones, Mark, Stackelroth, Jenny, van Kuilenburg, Rosita, Joubert, Warren, Faoagali, Joan, Looke, David, Harper, John and Clements, Archie (2009). Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study. 51st ASH Annual Meeting and Exposition, New Orleans, LA, U.S.A., 5-8 December 2009. Washington, DC, U.S.A.: American Society of Hematology.

Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study

2009

Conference Publication

WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaernia (AML)

Gray, J. X., McMillen, L., Saal, R., Lane, S., Mollee, P., Bird, R., Gill, D. and Marlton, P. (2009). WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaernia (AML). 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, United States, 5-8 December 2009. Washington, DC, United States: American Society of Hematology.

WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaernia (AML)

2009

Conference Publication

Sequential treatment with Rituximab and CHOP chemotherapy in B-Cell PTLD - moving forward to a first standard of care: Results from a prospective international multicenter trial

Trappe, Ralf, Choquet, Sylvain, Oertel, Stephan H.K., Leblond, Veronique, Dierickx, Daan, Mollee, Peter, Sender, Monica, Ekman, Tor, Zaucha, Jan Maciej, Reinke, Petra, Neuhaus, Ruth, Lehmkuhl, Hans, Dreyling, Martin H., Duhrsen, Ulrich, Salles, Gilles, Morschhauser, Franck, Jaccard, Arnaud, Lamy, Thierry, Anagnostopoulos, Ioannis, Raphael, Martine, Dorken, Bernd and Riess, Hanno (2009). Sequential treatment with Rituximab and CHOP chemotherapy in B-Cell PTLD - moving forward to a first standard of care: Results from a prospective international multicenter trial. 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, United States, 5 - 8 December 2009. Washington, DC, United States: American Society of Hematology.

Sequential treatment with Rituximab and CHOP chemotherapy in B-Cell PTLD - moving forward to a first standard of care: Results from a prospective international multicenter trial

2008

Conference Publication

Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro

Gill, Devinder, Burgess, Melinda, Knop, Louise, Mollee, Peter and McMillan, Nigel (2008). Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro. 50th ASH Annual Meeting, San Francisco, CA United States, 6-9 December 2008. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v112.11.3157.3157

Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro

2008

Conference Publication

Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) population

Keane, Colm G., Mollee, Peter, Marlton, Paula and Gill, Devinder (2008). Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) population. 50th ASH Annual Meeting, San Francisco, CA United States, 6-9 December 2008. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v112.11.4014.4014

Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) population

2008

Journal Article

A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation

Hourigan, Matthew J., Doecke, James, Mollee, Peter N., Gill, Devinder S., Norris, Debra, Johnson, David W. and Gandhi, Maher K. (2008). A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation. British Journal of Haematology, 141 (6), 904-907. doi: 10.1111/j.1365-2141.2008.07149.x

A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation

2008

Journal Article

Prolonged haematological toxicity from the hyper-CVAD regimen: Manifestations, frequency, and natural history in a cohort of 125 consecutive patients

Gill, Saar, Lane, Steven, Crawford, Julie, Cull, Gavin, Joske, David, Joske, David, Marlton, Paula, Mollee, Peter, Prince, Miles and Seymour, John (2008). Prolonged haematological toxicity from the hyper-CVAD regimen: Manifestations, frequency, and natural history in a cohort of 125 consecutive patients. Annals of Hematology, 87 (9), 727-734. doi: 10.1007/s00277-008-0488-6

Prolonged haematological toxicity from the hyper-CVAD regimen: Manifestations, frequency, and natural history in a cohort of 125 consecutive patients

2008

Journal Article

A 1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor accute myeloid leukemia and predicts subsequent morphologic relapse

Lane, Steven, Saal, Russell, Mollee, Peter, Jones, Mark, Grigg, Andrew, Taylor, Kerry, Seymour, John, Kennedy, Glen, Williams, Bronwyn, Grimmett, Karen, Griffiths, Vanessa, Gill, Devinder, Hourigan, Matthew and Marlton, Paula (2008). A 1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor accute myeloid leukemia and predicts subsequent morphologic relapse. Leukemia & Lymphoma, 49 (3), 517-523. doi: 10.1080/10428190701817266

A 1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor accute myeloid leukemia and predicts subsequent morphologic relapse

2008

Conference Publication

Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro

Gill, Devinder, Burgess, Melinda, Knop, Louise, Mollee, Peter and McMillan, Nigel (2008). Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro. 50th Annual Meeting of the American- Society-of-Hematology, San Francisco, CA, United States, 6 - 9 December 2008. Washington, DC, United States: American Society of Hematology.

Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro

2008

Conference Publication

Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases - Analytical and clinical correlations

Tate, J.R., Bazeley, S., Sykes, S. and Mollee, P. (2008). Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases - Analytical and clinical correlations. 60th Annual Meeting of the American Association for Clinical Chemistry, Washington, DC, United States, 27-31 July 2008. Washington, DC, United States: American Association for Clinical Chemistry.

Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases - Analytical and clinical correlations

2007

Conference Publication

Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients

Mollee, Peter, Hourigan, Matthew, Johnson, David, Jones, Mark, Isbel, Nikki, Hawley, Carmel, Marlton, Paula, Gandhi, Maher, Campbell, Scott and Gill, Devinder (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. 49th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA USA, 8-11 December 2007. Washington, DC USA: American Society of Hematology.

Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients

2007

Conference Publication

JAK2 V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET)

Weston, Helen, Bird, Robert, Griffiths, Vanessa, Jones, Mark, Grimmett, Karen, Saal, Russell, Mills, Anthony K., Gill, Devinder, Marlton, Paula and Mollee, Peter (2007). JAK2 V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET). 49th ASH Annual Meeting, Atlanta, GA United States, 8-11 December 2007. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v110.11.2551.2551

JAK2 V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET)

2007

Journal Article

Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis

Morris, K. L., Tate, J. R., Gill, D., Kennedy, G., Wellwood, J., Marlton, P., Bird, R., Mills, A. K. and Molle, P. (2007). Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. Internal Medicine Journal, 37 (7), 456-463. doi: 10.1111/j.1445-5994.2007.01368.x

Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis

2007

Journal Article

Palifermin-induced Acanthosis Nigricans

Lane, S. W., Manoharan, S. and Mollee, P. N. (2007). Palifermin-induced Acanthosis Nigricans. Internal Medicine Journal, 37 (6), 417-418. doi: 10.1111/j.1445-5994.2007.01340.x

Palifermin-induced Acanthosis Nigricans

2007

Journal Article

Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders

Gandhi, M., Wilkie, G. M., Dua, U., Mollee, P., Grimmett, K., Williams, T., Whitaker, N., Gill, D. and Crawford, D. (2007). Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. American Journal of Transplantation, 7 (5), 1293-1299. doi: 10.1111/j.1600-6143.2007.01796.x

Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders

2007

Journal Article

Analytical performance of serum free light-chains assay

Tate, Jillian R., Mollee, Peter, Dimeski, Goce, Carter, Andrew C. and Gill, Devinder (2007). Analytical performance of serum free light-chains assay. Clinica Chimica Acta, 380 (1-2), 250-251. doi: 10.1016/j.cca.2007.02.004

Analytical performance of serum free light-chains assay

2007

Journal Article

Epstein-Barr virus T-cell immunity despite rituximab

Nehring, Angela K., Dua, Ujjwal, Mollee, Peter, Gill, Devinder, Grimmett, Karen, Khanna, Rajiv, Moss, Denis and Gandhi, Maher K. (2007). Epstein-Barr virus T-cell immunity despite rituximab. British Journal of Haematology, 136 (4), 628-632. doi: 10.1111/j.1365-2141.2006.06482.x

Epstein-Barr virus T-cell immunity despite rituximab

2007

Journal Article

Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases

Tate, Jillian R., Mollee, Peter, Dimeski, Goce, Carter, Andrew C. and Gill, Devinder (2007). Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clinica Chimica Acta, 376 (1-2), 30-36. doi: 10.1016/j.cca.2006.07.011

Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases

2007

Conference Publication

Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients

Hourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. American Transplant Congress, San Francisco, CA, USA, 5-9 May 2007. Oxford, England: Wiley-Blackwell. doi: 10.1111/j.1600-6143.2007.01811.x

Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients